Tekla Capital Management LLC Editas Medicine, Inc. Transaction History

Tekla Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $596,511 - $1.11 Million	-15,190 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $603,194 - $1.38 Million	15,190 New	15,190 $638,000
Q3 2020 Nov 13, 2020	SELL	$28.06 - $37.16 $3.65 Million - $4.84 Million	-130,201 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$14.88 - $32.78 $263,941 - $581,451	-17,738 Reduced 11.99%	130,201 $2.58 Million
Q3 2019 Nov 13, 2019	BUY	$22.49 - $26.81 $2.32 Million - $2.76 Million	102,950 Added 228.83%	147,939 $3.36 Million
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $648,785 - $879,409	-31,679 Reduced 41.32%	44,989 $1.11 Million
Q3 2018 Nov 13, 2018	SELL	$27.65 - $38.39 $1.69 Million - $2.35 Million	-61,133 Reduced 44.36%	76,668 $2.44 Million
Q1 2018 May 14, 2018	BUY	$29.84 - $44.08 $4.11 Million - $6.07 Million	137,801 New	137,801 $4.57 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $183M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.